© Globe Newswire
12.11.2024
CELC
LISTED
NASDAQ
Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences
News Preview
MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following inves...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2024
LEGN
LISTED
NASDAQ
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
News Preview
SOMERSET, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its third quarter 2024 unaudited financial results and key corporate highlights....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2024
AUTL
LISTED
NASDAQ
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
News Preview
Autolus Therapeutics Reports Third Quarter 2024 Financial Results
and Business Updates...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
12.11.2024
COLO B
LISTED
CPH
Coloplast A/S - Notice of Annual General Meeting 2024
News Preview
The Annual General Meeting of Coloplast A/S will be held onThursday, 5 December 2024 at 3:30 pm CETat the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark.The notice of the Annual General Meeting is enclosed....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
12.11.2024
ILM1
LISTED
XETR
Medios AG verzeichnet Rekordquartal Q3 2024 bei deutlichem Ergebnis- und Margenanstieg
News Preview
Pressemitteilung
Medios AG verzeichnet Rekordquartal Q3 2024 bei deutlichem Ergebnis- und Margenanstieg
EBITDA pre1 erreicht im dritten Quartal 2024 24,6 Mio. € (+42,9 %) und damit neuen Rekord
EBITDA-pre1-Marge liegt im dritten Quartal 2024 bei 5,0 %
Geschäftsbereich Patientenindividuelle Therapien wächst gegenüber Vorjahresquartal im EBITDA ......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.11.2024
ILM1
LISTED
XETR
Medios AG reports record quarter Q3 2024 with significant increase in earnings and margins
News Preview
Press release
Medios AG reports record quarter Q3 2024 with significant increase in earnings and margins
EBITDA pre1 reaches €24.6 million (+42.9%) in the third quarter of 2024, setting a new record
EBITDA pre1 margin of 5.0% in the third quarter of 2024
Patient-Specific Therapies segment grows by more than 10% in EBITDA pre1 compared to the......
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2024
LIVN
LISTED
NASDAQ
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. Together with its safety endpoints, the RCT achieved statistical significance of its primary end...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.11.2024
DBV
LISTED
EURONEXT
DBV Technologies Announces Plan to Implement ADS Ratio Change
News Preview
Châtillon, France, November 11, 2024...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.11.2024
FYB
LISTED
XETR
Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard
News Preview
Press Release // November 11, 2024Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard
Dr. Stefan Glombitza has been appointed as CEO for three more years and will lead Formycon through the next phase of the company's development
Formycon shares will be admitt......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.11.2024
FYB
LISTED
XETR
Formycon verlängert Vorstandsvertrag für CEO Dr. Stefan Glombitza bis 2027 und erhält Zulassung für Handel im Prime Standard
News Preview
Pressemitteilung // 11. November 2024
Formycon verlängert Vorstandsvertrag für CEO Dr. Stefan Glombitza bis 2027 und erhält Zulassung für Handel im Prime Standard
Dr. Stefan Glombitza wird für drei weitere Jahre zum Vorstand (CEO) bestellt und wird Formycon durch die nächste Phase der Unternehmensentwicklung führen
Formycon-Aktien erhalten Zula......
Themefolio
Profiler
Peergroup
© Globe Newswire
11.11.2024
ZEAL
LISTED
CPH
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
News Preview
Company announcement – No. 50 / 2024...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2024
TEM
LISTED
NASDAQ
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open.
Tempus recently conducted a retrospec...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
11.11.2024
ZLAB
LISTED
NASDAQ
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [Efgartigimod Alfa Injection (Subcutaneous Injection)] for the treatment of adult pa...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.11.2024
MURA
LISTED
NASDAQ
Mural Oncology to Participate in Two Upcoming Investor Conferences
News Preview
WALTHAM, Mass. and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that members of the management team will participat...
Themefolio
Profiler
Peergroup
© PR Newswire
11.11.2024
SOBI
LISTED
STO
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
News Preview
STOCKHOLM, Nov. 11, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the "Meeting"), to be held on Wednesday, 11 December 2024 at 09.00 at the offices of Mannheimer Swartling Advokatbyrå, Norrlandsgatan 21, Stockholm, Sweden. Registr...
Themefolio
Profiler
Peergroup
© PR Newswire
11.11.2024
SOBI
LISTED
STO
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
News Preview
STOCKHOLM, Nov. 11, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the "Meeting"), to be held on Wednesday, 11 December 2024 at 09.00 at the offices of Mannheimer Swartling Advokatbyrå, Norrlandsgatan 21, Stockholm, Sweden. Registr...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2024
ALM
LISTED
BME
Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth
News Preview
Almirall, S.A. (ALM), a global biopharmaceutical company based in Barcelona, today announced its year to date financial results at the third quarter of 2024. Almirall continued to deliver strong sales growth in the first nine months of 2024 which were driven by the dermatology business, and especially the biologics portfolio in Europe. Net Sales i...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.11.2024
CLBX
LISTED
AIMX
Angle PLC Announces Parsortix enriched CTC & ctDNA in NSCLC patients
News Preview
ANGLE plc ("the Company")DNA ANALYSIS OF PARSORTIX-ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIBThe addition of CTC-DNA analysis to clinical trials could identify patients developing treatment resistance prior to disease progressionCTC analysis identifies druggable targ...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2024
AUTL
LISTED
NASDAQ
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
News Preview
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2024
TEM
LISTED
NASDAQ
Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, which convenes in Houston, Texas, from November 6-10, 2024.
“Presenting our latest res...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2024
CHEMM
LISTED
CPH
Notification of managers’ transactions
News Preview
ANNOUNCEMENT NO. 283...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2024
IMCR
LISTED
NASDAQ
Immunocore to present at upcoming investor conferences
News Preview
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2024
AMRX
LISTED
NASDAQ
Amneal Reports Third Quarter 2024 Financial Results
News Preview
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the third quarter ended September 30, 2024.
“Q3 was an excellent quarter where we continued to drive strong financial results across our diversified business and we announced three strategic actions to solidify our long-term growth. First, we l...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2024
REC
LISTED
EURONEXT
RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%
News Preview
Milan, November 8th, 2024 – The Board of Directors of Recordati S.p.A. approved the Group’s Interim Report on 30th September 2024, representing additional voluntary financial reporting (6). The Report was prepared using the assessment, measurement and recognition criteria prescribed by international accounting standards (IFRS). The Group’s Interim...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
TEM
LISTED
NASDAQ
Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians to order, is a multimodal biomarker that can be used as a prognostic indicator for adult pa...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
CYRX
LISTED
NASDAQ
Cryoport Reports Third Quarter 2024 Financial Results
News Preview
Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year Supported a record total of 691 global clinical trials as of September 30, 2024Company reaffirmed full year 2024 revenue guidance of $225 to $235 millionNASHVILLE, Tenn., Nov. 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
DFTX
LISTED
NASDAQ
MindMed Reports Third Quarter 2024 Financial Results and Business Updates
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended September 30, 2024, and provided a business update.
“This is a pivotal moment for MindMed as we prepa...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2024
MURA
LISTED
NASDAQ
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
News Preview
Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune activation...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
INDV
LISTED
NASDAQ
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
News Preview
RICHMOND, Va., Nov. 7, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a letter from Oaktree Capital Management LP ("Oaktree") to the Board of Indivior....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2024
CHEMM
LISTED
CPH
Growth in revenue and operating profit
News Preview
Trading statement for Q1 2024/25 (1 July - 30 September 2024)...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
IMMNOV
LISTED
STO
Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium
News Preview
SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Immunovia (NASDAQ STOCKHOLM: IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual meeting of the PRECEDE Consortium, a collaboration of 51 pancreatic centers worldwide conducting unprecedented research for the early detection of pancreatic can...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
IMMNOV
LISTED
STO
Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium
News Preview
SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Immunovia (NASDAQ STOCKHOLM: IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual meeting of the PRECEDE Consortium, a collaboration of 51 pancreatic centers worldwide conducting unprecedented research for the early detection of pancreatic can...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
EHAB
LISTED
NYSE
Enhabit Home Health & Hospice Appoints Ryan Solomon as Chief Financial Officer
News Preview
Enhabit, Inc. (NYSE: EHAB), (“Enhabit”), a leading home health and hospice provider, today announced the appointment of Ryan Solomon as its next chief financial officer (CFO), effective Dec. 9, 2024. Mr. Solomon’s appointment follows the previously announced transition of Crissy Carlisle, CFO.
Mr. Solomon brings to Enhabit over 20 years of corpor...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2024
CELC
LISTED
NASDAQ
Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call
News Preview
MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2024 after the market closes on Thursday, November 14, 2024. Management will host a webcast/te...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
RAY B
LISTED
STO
Institut Curie selects RayStation for proton planning
News Preview
STOCKHOLM, Nov. 7, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that Institut Curie, spread over three radiotherapy centers, located in Paris, Orsay, and Saint-Cloud, France, has placed an order for the treatment planning system RayStation®*. Institut Curie is part of the French hospital network Unicancer, and the...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2024
NSIS B
LISTED
CPH
Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8%
News Preview
Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance has led Novonesis to now expect full-year organic sales growth to be at the upper end of the 7-8% range, and the adjusted EBITDA margin is con...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2024
NSIS B
LISTED
CPH
Trading statement 9M 2024
News Preview
Organic pro forma sales growth of 9%, including 11% in the third quarter. Full-year organic sales growth outlook now expected at the upper end of the 7-8% range and the adjusted EBITDA margin confirmed between 35.5-36.5%....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2024
ZEAL
LISTED
CPH
Zealand Pharma Announces Financial Results for the First Nine Months of 2024
News Preview
Company announcement – No. 49 / 2024...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
EHAB
LISTED
NYSE
Enhabit Reports Third Quarter 2024 Financial Results
News Preview
Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the third quarter ended September 30, 2024.
“Our continued progress in our strategies during the third quarter resulted in Adjusted EBITDA growth year over year and strong free cash flow generation that led to further debt red...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
BLUE
LISTED
NASDAQ
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it partially adjourned its annual meeting of stockholders (“Annual Meeting”) on Wednesday, November 6, 2024, to allow the Company to solicit additional votes to obtain approval of Proposal 4, a reverse stock split, as described in the Company's definitive prox...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2024
RXRX
LISTED
NASDAQ
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
News Preview
SALT LAKE CITY, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its third quarter ending September 30, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2024
GN
LISTED
CPH
Interim Report Q3 2024: Further margin expansion and strong cash flow despite mixed growth across divisions
News Preview
Highlights...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2024
GN
LISTED
CPH
Update of financial guidance for 2024
News Preview
GN has throughout the year increased its earnings power and cash flow generation, leading to an upgrade of the guidance on free cash flow excl. M&A to “DKK >1,100 million” and a confirmation of the EBITA margin guidance of “12 to 13%”. Following a somewhat softer market development than earlier anticipated for Enterprise and Gaming, GN adjus...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2024
GMAB
LISTED
CPH
Genmab Announces Financial Results for the First Nine Months of 2024
News Preview
November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
BIOA B
LISTED
STO
BrainTransporter™ dramatically improves antibody delivery to the brain
News Preview
STOCKHOLM, Nov. 6, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the 16th annual Protein & Antibody Engineering Summit (PEGS) conference in Barcelona, Spain. The BT platform uses active Transferrin Receptor (TfR)-mediated transport, e...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
BIOA B
LISTED
STO
BrainTransporter™ dramatically improves antibody delivery to the brain
News Preview
STOCKHOLM, Nov. 6, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the 16th annual Protein & Antibody Engineering Summit (PEGS) conference in Barcelona, Spain. The BT platform uses active Transferrin Receptor (TfR)-mediated transport, e...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
SLP
LISTED
NASDAQ
Simulations Plus to Participate in the Stephens Annual Investment Conference
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in a fireside chat at the Stephens Annual Investment Conferen...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2024
INSP
LISTED
NYSE
Inspire Medical Systems, Inc. to Present at Jefferies London Healthcare Conference
News Preview
MINNEAPOLIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Jefferies London Heal...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2024
IMCR
LISTED
NASDAQ
Immunocore reports third quarter financial results and provides a business update
News Preview
Immunocore reports third quarter financial results and provides a business update...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
BIOA B
LISTED
STO
Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET
News Preview
STOCKHOLM, Nov. 6, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) will publish the company's third quarter report for July - September 2024 on Thursday, November 14, 2024, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on Nov...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2024
BIOA B
LISTED
STO
Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET
News Preview
STOCKHOLM, Nov. 6, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) will publish the company's third quarter report for July - September 2024 on Thursday, November 14, 2024, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on Nov...
Themefolio
Profiler
Peergroup
© EQS Newswire
06.11.2024
EVT
LISTED
XETR
Strategische Fortschritte und erfolgreiche Expansion in einem schwierigen Marktumfeld
News Preview
Prognose für 2024 bestätigt: Umsatzerlöse und bereinigtes EBITDA für das Gesamtjahr 2024 liegen im Plan, trotz herausfordernder Marktbedingungen
Robustes Wachstum von Just – Evotec Biologics durch den Start weiterer Projekte zusammen mit Sandoz sowie Fortschritte bei Forschungspartnerschaften
Erfolgreiche Erweiterungen & Expansion mit BMS und......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.11.2024
EVT
LISTED
XETR
Strategic Progress and Successful Expansion Amid Challenging Market Conditions
News Preview
Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditions
Robust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnerships
Successful extensions & expansions with BMS and Novo Nordisk; new collaboration......
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2024
IBAB
LISTED
EURONEXT
IBA signs contract with SteriLab for E-beam sterilization solution in the Dominican Republic
News Preview
Fourth agreement secured by IBA Industrial Solutions in past six weeks...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.11.2024
EVT
LISTED
XETR
Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions
News Preview
Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditionsRobust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnershipsSuccessful extensions & expansions with BMS and Novo Nordisk; new collaboration with...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
ANAB
LISTED
NASDAQ
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
News Preview
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended Sept. 30, 2024 and provided a business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
ANAB
LISTED
NASDAQ
Anaptys Announces Participation in November and December Investor Conferences
News Preview
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multi...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
GMAB
LISTED
CPH
Genmab to Present at Jefferies London Healthcare Conference
News Preview
Media ReleaseCOPENHAGEN, Denmark; November 5, 2024...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
BLUE
LISTED
NASDAQ
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) today announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell disease who have a history of vaso-occlusive events and patients with beta-thalassemia who require regular blood transfusions will be presented at the 66th American Society of Hematology (...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
LEGN
LISTED
NASDAQ
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
News Preview
New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
